Targacept Inc
(NASDAQ: TRGT)
2.32
-0.02
-0.85%
After Hours :
2.33
+0.01
+0.43%

Open

2.34

Previous Close

2.34

Volume (Avg)

45.20K (194.38K)

Day's Range

2.25-2.35

52-wk Range

2.25-6.11

Market Cap.

78.40M

Dividend Rate ( Yield )

-

Beta

1.86

Shares Outstanding

33.79M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 3.63M

    • Net Income

    • -46.70M

    • Market Cap.

    • 78.40M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -22,871.76

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.86

    • Forward P/E

    • -

    • Price/Sales

    • 357.14

    • Price/Book Value

    • 0.67

    • Price/Cashflow

    • -1.77

      • EBITDA

      • -46.10M

      • Return on Capital %

      • -33.84

      • Return on Equity %

      • -35.90

      • Return on Assets %

      • -33.84

      • Book Value/Share

      • 3.46

      • Shares Outstanding

      • 33.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1-year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -97.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-year Annual Average

          • -28.98

          • 63.43

          • Net Income

            5-year Annual Average

          • -

          • 10.65

          • Dividends

            5-year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -21,268.06

            • 39.38

            • Net Profit Margin

            • -22,871.76

            • 31.33

            • Average Gross Margin

              5-year Annual Average

            • 86.40

            • 82.99

            • Average Pre-tax Margin

              5-year Annual Average

            • -289.70

            • 33.42

            • Average Net Profit Margin

              5-year Annual Average

            • -290.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 13.17

              • 2.92

              • Quick Ratio

              • 13.04

              • 2.35

              • Interest Coverage

              • -1,207.92

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 3.46

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.60

                • 217.39

                • P/E Ratio 5-Year High

                • -20.79

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.55

                • 124.82

                • Price/Sales Ratio

                • 370.37

                • 9.52

                • Price/Book Value

                • 0.68

                • 8.61

                • Price/Cash Flow Ratio

                • -1.77

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5-Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Pay-out Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-year Average)

                      • -35.90

                        (-17.90)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-year Average)

                      • -33.84

                        (-9.90)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-year Average)

                      • -35.59

                        (-17.20)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08K

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -47.22M
                      Operating Margin
                      -1,301.07
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -1.77
                      Ownership

                      Institutional Ownership

                      93.34%

                      Top 10 Institutions

                      75.41%

                      Mutual Fund Ownership

                      16.06%

                      Float

                      68.06%

                      5%/Insider Ownership

                      0.30%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Biotechnology Discovery

                      •  

                        1,863,661

                      • 156.58

                      • 5.52

                      • Vanguard Total Stock Mkt Idx

                      •  

                        626,364

                      • 0.00

                      • 1.85

                      • Prudential Jennison Health Sciences

                      •  

                        548,417

                      • 0.00

                      • 1.62

                      • Vanguard Extended Market Index Fund

                      •  

                        389,184

                      • 2.28

                      • 1.15

                      • Fidelity® Small Cap Stock Fund

                      •  

                        316,533

                      • -27.97

                      • 0.94

                      • TFS Market Neutral Fund

                      •  

                        275,351

                      • -17.20

                      • 0.81

                      • Swedbank Robur Medica

                      •  

                        193,262

                      • -22.90

                      • 0.59

                      • Franklin Biotechnology Discovery Fund

                      •  

                        191,432

                      • -77.47

                      • 0.57

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        150,431

                      • 0.00

                      • 0.45

                      • Bridgeway Ultra Small Company Market

                      •  

                        103,900

                      • 0.00

                      • 0.31

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Bvf Inc

                      •  

                        6,655,128

                      • +7.83%

                      • 19.69

                      • NEA Management Company, LLC

                      •  

                        4,566,666

                      • 0.00%

                      • 13.51

                      • Franklin Advisers, Inc.

                      •  

                        2,713,347

                      • +14.77%

                      • 8.03

                      • Camber Capital Management LLC

                      •  

                        1,560,000

                      • 0.00%

                      • 4.62

                      • BlackRock Fund Advisors

                      •  

                        1,023,278

                      • -23.20%

                      • 3.03

                      • Vanguard Group, Inc.

                      •  

                        973,041

                      • -2.97%

                      • 2.88

                      • Technical Financial Services LLC

                      •  

                        740,745

                      • +149.50%

                      • 2.19

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Targacept, Inc., is a biopharmaceutical company engaged incorporated in the year 2001. The Company is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disord...moreers of the central nervous system. The Company’s NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs, which are found on nerve cells throughout the nervous system and serves as key regulators of nervous system activity. The Company’s product candidates are TC-5214, TC-1734, TC-6499, AZD1446 or TC-6683, TC-5619 and TC-6987. It has multiple clinical-stage product candidates and preclinical programs in areas where there are significant medical needs and commercial potential, as well as proprietary drug discovery technologies. It also has a cognition-fo...morecused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. In July 2007, it entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. The Company is conducting an ongoing Phase 2b clinical trial of TC-5214. The Company and AstraZeneca are conducting an ongoing exploratory Phase 2 trial of TC-1734 in adults with ADHD. TC-5619 is a novel small molecule that the company plans to develop for cognitive dysfunction in schizophrenia or potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the a7 NNR. AZD1446 or TC-6683 is a novel small molecule that it discovered and advanced as part of the preclinical research collaboration that it is conducting with AstraZeneca. AZD1446 modulates the activity of the a4ß2 NNR and is in development for Alzheimer’s disease, ADHD or one or more other conditions characterized by cognitive impairment. The Company is subject to government regulations.lessless

                      Key People

                      Stephen A. Hill,B.M.

                      CEO/Director/President

                      John P. Richard

                      Chairman of the Board/Director

                      Alan A. Musso

                      Assistant Secretary/CFO/Senior VP, Divisional/Treasurer

                      Steven M. Toler

                      Vice President, Divisional

                      Mr. Charles Blixt

                      Director

                      • Targacept Inc

                      • 100 North Main Street

                      • Winston-Salem, NC 27101

                      • USA.Map

                      • Phone: +1 336 480-2100

                      • Fax: +1 336 480-2107

                      • targacept.com

                      Incorporated

                      1997

                      Employees

                      40

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing in to my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: